56981-97-6

Upstream product

• 99-36-5 1-methoxycarbonyl-3-methylbenzene 
• 603-35-0 triphenylphosphine 
• 1129-28-8 3-methoxycarbonylbenzyl bromide 

Downstream Products

• 85431-05-6 methyl 3-<3-(benzyloxy)-1-propenyl>benzoate 
• 98459-89-3 3-[(Z)-2-(12-Fluoro-benzo[c]phenanthren-2-yl)-vinyl]-benzoic acid methyl ester 
• 98460-01-6 3-[(E)-2-(11-Fluoro-dibenzo[c,g]phenanthren-9-yl)-vinyl]-benzoic acid methyl ester 
• 88856-28-4 ω,ω-o-Phenylen-di-(m-trans-vinyl-benzoesaeure) 
• 139425-23-3 (E)-methyl 3-styrylbenzoate 
• 74543-63-8 {3-[2-(4-Dimethylamino-phenyl)-ethyl]-phenyl}-methanol 
• 74543-65-0 {4-[2-(3-Methoxymethyl-phenyl)-ethyl]-phenyl}-dimethyl-amine 
• 63368-08-1 3-Carboxy-3'-hydroxy-4'-methoxydibenzyl 
• 63368-01-4 3-Methoxycarbonyl-3'-hydroxy-4'-methoxydibenzyl 
• 63368-10-5 3-Ethoxycarbonyl-3'-hydroxy-4'-methoxydibenzyl 
• 63368-12-7 3-Hydroxymethyl-3'-hydroxy-4'-methoxydibenzyl 
• 847957-36-2 methyl 3-((E)-2-((1S,2S,5R)-2-benzyloxycarbonylamino-5-(tert-butoxycarbonylamino)cyclohexyl)vinyl)benzoate 
• 99-36-5 1-methoxycarbonyl-3-methylbenzene 
• 96841-94-0 1,2-bis(m-methoxycarbonylphenyl)ethane 

Relevant academic research and scientific papers

Reactions of benzyltriphenylphosphonium salts under photoredox catalysis

The development of benzyltriphenylphosphonium salts as alkyl radical precursors using photoredox catalysis is described. Depending on substituents, the benzylic radicals may couple to form C-C bonds or abstract a hydrogen atom to form C-H bonds. A natural product, brittonin A, was also synthesized using this method.

COMPOUNDS FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE

Disclosed are compounds that can modulate DDAH and the amount of asymmetric dimethylarginine (ADMA) in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to treat and/or prevent diseases associated with elevated or low levels of DDAH and ADMA.

NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF

A compound of the Formula (I) is disclosed: (I) or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification. Also described are a pharmaceutical composition comprising the same and a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, lung, and liver, and kindey diseases, and hair loss using the same.

Syntheses and evaluation of simplified pretubulysin analogues

The syntheses of new tubulysin analogues are described, in which the central amino acid, tubuvaline, is replaced by the rather simple building blocks phenyltubuvaline and phenoxytubuvaline. These analogues can be obtained in only two to three steps from e

PYRIDYL NON-AROMATIC NITROGENATED HETEROCYCLIC-1-CARBOXYLATE ESTER DERIVATIVE

[Problem] To provide a compound usable for treatment of diseases associated with fatty acid amide hydrolase (FAAH), especially for treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain. [Means for Solution] We have found that a novel pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative and its pharmaceutically acceptable salt has a potent FAAH-inhibitory activity. Further, the pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative of the present invention has an excellent effect for increasing an effective bladder capacity, an excellent effect for relieving urinary frequency and an excellent anti-allodynia effect, and is therefore usable for treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain.

Synthesis and evaluation of 2′-substituted 4-(4′-carboxy- or 4′-carboxymethylbenzylidene)-N-acylpiperidines: Highly potent and in vivo active steroid 5α-reductase type 2 inhibitors

Sixteen compounds derived from N-acyl-4-benzylidenepiperidine-4′-carboxylic acids were synthesized and evaluated for inhibition of rat and human steroid 5α-reductase isozymes types 1 and 2. In the dicyclohexylacetyl series, fluorination in the 2-position of the benzene nucleus (15), exchange of the carboxy group by a carboxymethyl moiety (20), and combination of both structural modifications (25) led to highly active inhibitors of the human type 2 isozyme (IC50 values: 15, 11 nM; 20, 6 nM; 25, 7 nM; finasteride, 5 nM). In vivo all compounds tested markedly reduced the prostate weights in castrated testosterone-treated rats. Oral activity was shown for compound 7. From the finding that compound 15 is active in the rat, although it is a rather poor inhibitor of the rat enzyme and is a strong inhibitor of the human enzyme, it is concluded that it should be highly potent in men.

HELICENES : SYNTHESE PHOTOCHIMIQUE ET ETUDE RMN 19F, 13 C ET 1H DE FLUORO-1-HEXAHELICENES ET FLUORO-1-HEPTAHELICENES.

1-Fluorohexahelicene, 1-fluoroheptahelicene and 12 substituted derivatives of these fluorohelicenes have been synthesized by the photocyclodehydrogenation of 1-fluro-11-styrylbenzophenanthrenes (Table 2) and 1-fluoro-13-styrylpentahelicenes (Table 4) respectively.The photocyclisations to heptahelicenes were accompanied in five cases, by a side reaction, namely a photodefluoration.A new synthesis of heptahelicenes is described (25-->18 : 40 percent). 1H, 19F and 13C-NMR spectra are discussed. 19F and 13C-NMR spectra of 1-fluoro-, 1-fluoro-13-methyl- and 1-fluoro-13-methoxycarbonylpentahelicene (8d, 8a and 8 R=-CO2CH3) are also included.